Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population.
Dayna R CeninSteffie K NaberIris Lansdorp-VogelaarMark A JenkinsDaniel D BuchananDavid B PreenHooi C EePeter O'LearyPublished in: Journal of gastroenterology and hepatology (2018)
The MLH1-Pathway is more cost-effective than BRAF-Pathway for all age-at-diagnosis thresholds. MMR immunohistochemistry tumor screening in individuals diagnosed with CRC aged < 70 years resulted in higher LS case detection at a reasonable cost. Further research into the yield of LS screening in CRC patients ≥ 70 years is needed to determine if universal screening is justified.